F-STAR THERAPEUTICS

f-star-therapeutics-logo

F-Star Therapeutics is a biopharmaceutical company dedicated to developing novel bispecific antibody products that provide a significant improvement over the current standard of care. Given its strong patent position, it is the only biopharmaceutical company with the ability to create and develop Fcab:tm: antibody fragments, and bispecific antibodies, by modifying the constant region of an antibody. In particular, F-starโ€™s Modular Antibody Technology:tm: enables rapid discovery and development... of bispecific antibodies by introducing additional binding sites to the constant region of an antibody and offers unprecedented ease in the development and manufacturing of bispecific monoclonal antibodies. Using the Modular Antibody Technology, F-star generates bispecific antibodies (mAb2:tm:) that possess the favourable characteristics of traditional monoclonal antibodies, without the production challenges often associated with other antibody formats. F-star is now applying its proprietary technology to the development of a pipeline of product candidates. Since its founding in 2006 the company has secured funding and support from leading VC investors: Aescap Venture, Atlas Venture, Novo Ventures and TVM Capital; as well as from renowned strategic corporate investors: Merck Serono Ventures, MP Healthcare Venture Management and SR One. In 2013, F-star established an asset-centric vehicle structure through the formation of F-star Alpha Ltd., which included out-licensing of FS102 from F-star to F-star Alpha Ltd. In October 2014 Bristol-Myers Squibb obtained an exclusive option to buy F-star Alpha. In addition the company has alliances with Boehringer Ingelheim and Merck Serono, each covering multiple targets. In 2011, F-star was selected by FierceBiotech as one of the Fierce 15 winners. F-star currently employs over 35 people at its research site in Cambridge, UK.

#People #Financial #Event #Website #More

F-STAR THERAPEUTICS

Social Links:

Industry:
Biopharma Biotechnology Pharmaceutical

Founded:
2006-01-01

Address:
Cambridge, Cambridgeshire, United Kingdom

Country:
United Kingdom

Website Url:
http://www.f-star.com

Total Employee:
51+

Status:
Active

Contact:
+43 (0)-72055-4215

Email Addresses:
[email protected]

Total Funding:
137.29 M USD

Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Apple Mobile Web Clips Icon WordPress Domain Not Resolving Wordpress Plugins Nginx Sitelinks Search Box



Current Advisors List

david-a-arkowitz_image

David A. Arkowitz Board Member and Chair of Audit Committee @ F-Star Therapeutics
Board_member
2020-11-01

florian-ruker_image

Florian Ruker Scientific Advisors @ F-Star Therapeutics
Advisor

jean-francois-formela_image

Jean-Francois Formela Member of the Board of Directors @ F-Star Therapeutics
Board_member
2006-12-21

roel-bulthuis_image

Roel Bulthuis Board Member @ F-Star Therapeutics
Board_member

axel-polack_image

Axel Polack Board Director @ F-Star Therapeutics
Board_member
2011-01-01

Current Employees Featured

james-sandy_image

James Sandy
James Sandy Chief Development Officer @ F-Star Therapeutics
Chief Development Officer
2022-03-01

eliot-forster_image

Eliot Forster
Eliot Forster CEO @ F-Star Therapeutics
CEO
2018-10-01

darlene-deptula-hicks_image

Darlene Deptula-Hicks
Darlene Deptula-Hicks Chief Financial Officer @ F-Star Therapeutics
Chief Financial Officer
2019-05-01

florian-ruker_image

Florian Ruker
Florian Ruker Co-Founder @ F-Star Therapeutics
Co-Founder

not_available_image

Jane Dancer
Jane Dancer coo @ F-Star Therapeutics
coo

Founder


florian-ruker_image

Florian Ruker

Stock Details


Company's stock symbol is NASDAQ:FSTX

Acquisitions List

Date Company Article Price
2020-11-20 Spring Bank Pharmaceuticals Spring Bank Pharmaceuticals acquired by F-Star Therapeutics 30 M USD

Investors List

aescap-venture_image

Aescap Venture

Aescap Venture investment in Post-IPO Equity - F-Star Therapeutics

atlas-venture_image

Atlas Venture

Atlas Venture investment in Post-IPO Equity - F-Star Therapeutics

sr-one_image

SR One

SR One investment in Post-IPO Equity - F-Star Therapeutics

merckventures_image

M Ventures

M Ventures investment in Post-IPO Equity - F-Star Therapeutics

merckventures_image

M Ventures

M Ventures investment in Series A - F-Star Therapeutics

aescap-venture_image

Aescap Venture

Aescap Venture investment in Series A - F-Star Therapeutics

mp-healthcare-venture-management-inc_image

MP Healthcare Venture Management

MP Healthcare Venture Management investment in Series A - F-Star Therapeutics

sr-one_image

SR One

SR One investment in Series A - F-Star Therapeutics

atlas-venture_image

Atlas Venture

Atlas Venture investment in Series A - F-Star Therapeutics

tvm-capital_image

TVM Capital

TVM Capital investment in Series A - F-Star Therapeutics

Key Employee Changes

Date New article
2022-03-01 F-star Therapeutics Appoints James Sandy as Chief Development Officer

Official Site Inspections

http://www.f-star.com Semrush global rank: 4.61 M Semrush visits lastest month: 2.2 K

  • Host name: 160.89.214.35.bc.googleusercontent.com
  • IP address: 35.214.89.160
  • Location: Mountain View United States
  • Latitude: 37.4043
  • Longitude: -122.0748
  • Metro Code: 807
  • Timezone: America/Los_Angeles
  • Postal: 94043

Loading ...

More informations about "F-Star Therapeutics" on Search Engine